European Commission Approves Menarini Group’s ORSERDU^® (Elacestrant) for the Treatment of Patients with ER⁺, HER2^– Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

The Menarini Group and Therapeutics Inc. announced today that the European Commission has approved ORSERDU®. With this approval, ORSERDU becomes the first and only therapy specifically indicated for the treatment of estrogen receptor (ER)+, HER2– tumors that harbor ESR1 mutations.